Comparison of Anticoagulation Prolongation vs. no Anticoagulation in STEMI Patients After Primary PCI (RIGHT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03664180

Recruitment Status : Completed

First Posted : September 10, 2018

Last Update Posted : May 3, 2023

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborators:

Chinese Academy of Medical Sciences, Fuwai Hospital

ACTION Study Group (Pitié-Salpêtrière Hospital), Paris, France

Information provided by (Responsible Party):

Shao-Ping Nie, Beijing Anzhen Hospital

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	November 23, 2022
Actual Study Completion Date :	November 23, 2022

Publications:

Yan Y, Wang X, Guo J, Li Y, Ai H, Gong W, Que B, Zhen L, Lu J, Ma C, Montalescot G, Nie S. Rationale and design of the RIGHT trial: A multicenter, randomized, double-blind, placebo-controlled trial of anticoagulation prolongation versus no anticoagulation after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Am Heart J. 2020 Sep;227:19-30. doi: 10.1016/j.ahj.2020.06.005. Epub 2020 Jun 20.

To Top